 With all these, the investigators hypothesize that treatment of locally advanced esophageal squamous cell carcinoma ESCCwith cetuximab in combination with paclitaxel, cisplatin and radiation may further improve clinical outcomes. This trial results will be important as it may support further studies for setting the new treatment standard for ESCC. 